Evaxion Biotech (NASDAQ:EVAX) is flying high today as the company’s personalized cancer therapy EVX-01 reached an important milestone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EVAX has now enrolled the first patient in the global Phase 2b trial of EVX-01which is being developed for the treatment of melanoma.
The trial is evaluating the efficacy and safety of the therapy in adults with metastatic melanoma.
Read full Disclosure